FIL Ltd reduced its holdings in shares of C.R. Bard, Inc. (NYSE:BCR) by 83.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,265 shares of the medical instruments supplier’s stock after selling 11,270 shares during the quarter. FIL Ltd’s holdings in C.R. Bard were worth $716,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. SRS Capital Advisors Inc. boosted its stake in shares of C.R. Bard by 0.7% during the 1st quarter. SRS Capital Advisors Inc. now owns 598 shares of the medical instruments supplier’s stock valued at $148,000 after buying an additional 4 shares during the last quarter. Alps Advisors Inc. boosted its stake in shares of C.R. Bard by 0.3% during the 2nd quarter. Alps Advisors Inc. now owns 1,921 shares of the medical instruments supplier’s stock valued at $607,000 after buying an additional 5 shares during the last quarter. KCM Investment Advisors LLC boosted its stake in shares of C.R. Bard by 0.5% during the 2nd quarter. KCM Investment Advisors LLC now owns 2,187 shares of the medical instruments supplier’s stock valued at $691,000 after buying an additional 10 shares during the last quarter. Parallel Advisors LLC boosted its stake in shares of C.R. Bard by 2.8% during the 2nd quarter. Parallel Advisors LLC now owns 513 shares of the medical instruments supplier’s stock valued at $164,000 after buying an additional 14 shares during the last quarter. Finally, Blair William & Co. IL boosted its stake in shares of C.R. Bard by 0.9% during the 1st quarter. Blair William & Co. IL now owns 3,492 shares of the medical instruments supplier’s stock valued at $865,000 after buying an additional 30 shares during the last quarter. Institutional investors own 79.22% of the company’s stock.

In related news, insider John P. Groetelaars sold 23,687 shares of the firm’s stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $318.73, for a total transaction of $7,549,757.51. Following the completion of the transaction, the insider now owns 31,445 shares in the company, valued at approximately $10,022,464.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.80% of the stock is owned by company insiders.

TRADEMARK VIOLATION WARNING: “C.R. Bard, Inc. (BCR) Shares Sold by FIL Ltd” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://www.thecerbatgem.com/2017/09/30/c-r-bard-inc-bcr-shares-sold-by-fil-ltd.html.

Several equities analysts have recently commented on the company. Jefferies Group LLC reiterated a “hold” rating on shares of C.R. Bard in a research note on Thursday, August 3rd. Zacks Investment Research lowered C.R. Bard from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st. BidaskClub lowered C.R. Bard from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 19th. Finally, BMO Capital Markets reissued a “hold” rating and set a $317.00 price target on shares of C.R. Bard in a research report on Tuesday, July 11th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $292.00.

Shares of C.R. Bard, Inc. (BCR) opened at 320.50 on Friday. The firm has a market capitalization of $23.29 billion, a price-to-earnings ratio of 42.08 and a beta of 0.60. The company’s 50 day moving average price is $320.07 and its 200 day moving average price is $299.22. C.R. Bard, Inc. has a 52-week low of $203.63 and a 52-week high of $324.58.

C.R. Bard (NYSE:BCR) last posted its earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.84 by $0.08. The business had revenue of $979.70 million during the quarter, compared to the consensus estimate of $976.53 million. C.R. Bard had a return on equity of 48.70% and a net margin of 14.99%. C.R. Bard’s revenue was up 5.2% on a year-over-year basis. During the same quarter last year, the company earned $2.54 EPS. Analysts forecast that C.R. Bard, Inc. will post $11.84 earnings per share for the current year.

About C.R. Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Stock Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related stocks with our FREE daily email newsletter.